

Enfu Hui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1377752/publications.pdf>

Version: 2024-02-01

15
papers

3,205
citations

687335

13
h-index

996954

15
g-index

21
all docs

21
docs citations

21
times ranked

5280
citing authors

#	ARTICLE	IF	CITATIONS
1	T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. <i>Science</i> , 2017, 355, 1428-1433.	12.6	1,229
2	Phase separation of signaling molecules promotes T cell receptor signal transduction. <i>Science</i> , 2016, 352, 595-599.	12.6	941
3	PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. <i>Immunity</i> , 2019, 51, 1059-1073.e9.	14.3	229
4	Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. <i>Cell Reports</i> , 2018, 24, 379-390.e6.	6.4	140
5	In vitro membrane reconstitution of the T-cell receptor proximal signaling network. <i>Nature Structural and Molecular Biology</i> , 2014, 21, 133-142.	8.2	136
6	Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. <i>Immunity</i> , 2022, 55, 512-526.e9.	14.3	118
7	Multiple Signaling Roles of CD3 μ and Its Application in CAR-T Cell Therapy. <i>Cell</i> , 2020, 182, 855-871.e23.	28.9	91
8	In vitro reconstitution of T cell receptor-mediated segregation of the CD45 phosphatase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9338-E9345.	7.1	83
9	PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. <i>Journal of Cell Biology</i> , 2020, 219, .	5.2	65
10	A Structural Role for the Synaptobrevin 2 Transmembrane Domain in Dense-Core Vesicle Fusion Pores. <i>Journal of Neuroscience</i> , 2015, 35, 5772-5780.	3.6	52
11	Immune checkpoint inhibitors. <i>Journal of Cell Biology</i> , 2019, 218, 740-741.	5.2	41
12	TCR-pMHC bond conformation controls TCR ligand discrimination. <i>Cellular and Molecular Immunology</i> , 2020, 17, 203-217.	10.5	25
13	Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors. <i>ELife</i> , 2021, 10, .	6.0	20
14	Understanding T cell signaling using membrane reconstitution. <i>Immunological Reviews</i> , 2019, 291, 44-56.	6.0	13
15	Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. <i>Hepatology</i> , 2022, 76, 630-645.	7.3	13